Last edition
News about "rolditamig deuderuxtecan"
Cipla Partners with CTTQ to Develop and Commercialise HER2-Targeted ADC in Emerging Markets
Cipla and CTTQ partner to expand access to TQB2102, an investigational HER2 bispecific ADC being evaluated across HER2-expressing cancers.
Rolditamig Deuderuxtecan | 01/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members